Venclexta (venetoclax)

P1/2, N=181, Active, not recruiting, Faron Pharmaceuticals Ltd | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027

Upregulation of SLC25A6 expression induced by the glutaminase inhibitor CB-839 sensitized cancer cells to the Bcl-2 inhibitor ABT-199. Our findings reveal a novel function of SLC25A6 that links metabolic stress to mitochondrial apoptosis via disruption of the MICOS complex. Combination treatments with mitochondrial apoptotic inducers represent a promising avenue for maximizing the efficacy of GMIs in cancer treatment.

P=N/A, N=250, Peking University People's Hospital; Peking University People's Hospital

P=N/A, N=20, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

P=N/A, N=60, The First Hospital of China Medical University; The First Hospital of China Medical University

P4, N=69, Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center

P=N/A, N=174, Recruiting, the Affiliated Hospital of Qingdao University; the Affiliated Hospital of Qingdao University

Combination of HDAC8i and Venetoclax synergistically reduced leukemia burden and significantly prolonged survival in both KMT2A::MLLT3 AML and patient-derived xenograft models. This study highlights the regulatory function of HDAC8 on STAT3-MYC and provides the proof-of-principle for targeting HDAC8 in combination with Venetoclax for the treatment of KMT2A-r AML.

In time-limited venetoclax-based regimens, achieving undetectable MRD (uMRD) strongly predicts durable off-treatment remission...Interpretation of MRD in biologically defined subgroups, including TP53-disrupted and IGHV-unmutated disease, as well as its evolving role following immune-based therapies, is also considered. We address the principal barriers to routine clinical implementation, along with the key questions being addressed by ongoing randomized studies that will determine whether MRD fully transitions from a prognostic biomarker to a practical therapeutic guide in CLL.

P3, N=40, Active, not recruiting, Fujian Medical University Union Hospital

Our study found that inhibition of XPO1 is a promising modality in the treatment of MDS, especially when combined with Venetoclax, which could be a potential target for MDS therapy.

Our study identified cellular and molecular biomarkers, notably CD56, that predict resistance to Rux + Ven, but further work is needed to understand and validate their effect in AML. This trial was registered at www.clinicaltrials.gov as #NCT03874052.